GLOBALDATA PLC Immunovia, a Swedish molecular diagnostics company specializing in early cancer detection, announced promising results for its latest pancreatic cancer diagnostic test in a clinical trial. With the demand for early disease diagnosis and a transformative shift towards accuracy and efficiency in In Vitro Diagnostics (IVD), Immunovia's new test contributes to the sector's increasingly crucial role in preventive healthcare and early disease detection, according to GlobalData, a leading data and analytics company.
According to GlobalData, the IVD market is projected to hit $33.4 billion by 2030, highlighting a shift toward improved accuracy and patient care. With the oncology diagnostics market, where Immunovia operates, estimated to grow from $1.5 billion in 2023 to $2.3 billion by 2030, the demand for early diagnosis and personalized medicine drives sector advancements.
Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, comments: "The market for oncology tests in IVD is witnessing significant growth and diversification. The growth of the market is supported primarily by the continuous increase in cancer prevalence due to the aging population and changing lifestyles.
"GlobalData projects that with the continuous advancements in technology and the introduction of innovative therapies, the landscape of oncology diagnostics is set to transform, offering new hope to millions affected by cancer."
Immunovia's test, an improved version of its previous IMMray PanCan-d test, demonstrated a specificity of 98% and a sensitivity of 75% for early stage 1 and 2 pancreatic cancers. It outperforms the commonly used CA19-9 biomarker, which some patients cannot produce, thereby expanding the test's applicability to a broader patient demographic. Immunovia is preparing for further studies, including a second phase of the model development and several analytical validation steps, aiming for a full clinical validation and a planned launch in 2025.
Stinchcombe adds: "The advancements in oncology diagnostics, fueled by companies like Immunovia, signify a major step forward in the accurate and early detection of cancer. With the industry focusing on both established and emerging diagnosis options, the scope for oncology diagnostics is widening, offering a brighter future for those affected by these conditions."
GlobalData's analysis underscores the importance of innovative diagnostic methods in the evolving oncology diagnostics landscape, highlighted by Immunovia's advancement with its next-generation IMMray PanCan-d test for pancreatic cancer. This test significantly enhances early detection capabilities with superior sensitivity and specificity compared to traditional biomarkers like CA19-9.
Leveraging Immunovia's expertise in molecular diagnostics and antibody microarray technology, the IMMray PanCan-d test broadens patient accessibility and promises improved outcomes by detecting pancreatic cancer at more treatable stages, setting a new standard in the field.
Stinchcombe concludes: "Amidst an aging population and the increasing prevalence of pancreatic cancer, the progress being made is not just promising; it is a beacon of hope for patients. The dynamic expansion of the IVD market, driven by relentless innovation and research, marks a hopeful era for patients."
If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.
Attachments
- Original Link
- Permalink
Disclaimer
GlobalData plc published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 May 2024 03:52:06 UTC.
